Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.
Is ZOM a stock to buy?
Zom stock has traded in a 52-week range with $2.91 as the ceiling and $0.24 as the floor. It is presently trading at $0.31 as of writing, closer to its 52-week bottom. The current price is testing the support formed by the Q4 2019 price at 0.3048, which has so far held firm.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Will Zomedica rise?
Zomedica Stock Price Forecast 2022-2023 The forecasted Zomedica price at the end of 2022 is $0.32 – and the year to year change +4%. The rise from today to year-end: +36% In the middle of 2022, we expect to see $0.30 per 1 Zomedica.
Does ZOM have a future?
Zomedica Corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20 The median estimate represents a +443.48% increase from the last price of 0.22.
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by ” changes at our current distributor that we believe have impacted its ability to market our products effectively” Those words likely startled investors, many of whom decided to sell their shares. Zomedica’s stock price dropped sharply on Thursday.
Is Zomedica being shorted?
What is Zomedica’s current short interest? Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 101,490,000 shares of ZOM short. 10.52% of Zomedica’s shares are currently sold short.
Is ZM a buy sell or Hold?
Zoom Stock: Is It A Buy Right Now? ZM stock owns an IBD Relative Strength Rating of only 20 out of a best-possible 99 The Relative Strength rating shows how a stock’s price performance stacks up against all other stocks over the last 52 weeks. Zoom stock holds an IBD Composite Rating of 46 out of a best possible 99.
Will sundial stock go up?
With Sundial’s current focus on investments, it’s likely that we’ll see revenue well above 2021 this year , due mainly to the acquisition of Alcanna and Sundial’s partnership with the SAF Group. Also, with strong growth predicted in the cannabis market in the near future, Sundial should be a huge beneficiary.
Is Sundial growers a buy?
Following the q3 earnings report, Sundial shares experienced a strong rally. However, even though SNDL is worth just over 50 cents and is under pressure to pass the $1-per-share level to remain in compliance with Nasdaq, here are three reasons why buying the stock ahead of earnings could be a good deal.
How many Zomedica shares does Vanguard own?
2022-02-14 – Vanguard Group Inc has filed a 13F-HR form disclosing ownership of 41,635,682 shares of Zomedica Pharmaceuticals Corp. (US:ZOM) with total holdings valued at $12,762,000 USD as of 2021-12-31.